Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results

M. Voskoboynik, L. Mileshkin, H. Gan, M. Millward, G. Au-Yeung, T. M. Meniawy, G. Kichenadasse, K. Zhang, M. Zhang, S. Mu, J. D. Lickliter

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

5 Citations (Web of Science)
Original languageEnglish
Number of pages1
JournalAnnals of Oncology
Volume30
DOIs
Publication statusPublished - Oct 2019
Externally publishedYes
Event44th Congress of the European-Society-for-Medical-Oncology (ESMO) - Barcelona, Spain
Duration: 27 Sept 20191 Oct 2019

Cite this